Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide, Thalidomide, and Lomustine in Advanced Melanoma
NCT00072345Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2003
- Primary completion
- Aug 2004
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide, thalidomide and lomustine in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective Response Rate. Started Jul 2003; status: completed.
02
Drugs
temozolomidethalidomidelomustine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00072345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072345.